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Abstract
Tissue transglutaminase (TG2) is a multi-functional protein, with enzymatic, GTP-ase and scaffold 
properties. TG2 interacts with fibronectin (FN) through its N-terminus domain, stabilizing integrin 
complexes, which regulate cell adhesion to the matrix. Through this mechanism, TG2 participates 
in key steps involved in metastasis in ovarian and other cancers. High throughput screening 
identified several small molecule inhibitors (SMIs) for the TG2/FN complex. Rational medicinal 
chemistry optimization of the hit compound (TG53) led to second generation analogues (MT1–6). 
ELISA demonstrated that these analogues blocked TG2/FN interaction and bio-layer 
interferometry (BLI) showed that the SMIs bound to TG2. The compounds also potently inhibited 
cancer cell adhesion to FN and decreased outside-in signaling mediated through the focal adhesion 
kinase (FAK). Blockade of TG2/FN interaction by the small molecules caused membrane ruffling, 
delaying the formation of stable focal contacts and mature adhesions points and disrupted 
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organization of the actin cytoskeleton. In an in vivo model measuring intraperitoneal (ip) 
dissemination, MT4 and MT6 inhibited the adhesion of ovarian cancer (OC) cells to the 
peritoneum. Pre-treatment with MT4 also sensitized OC cells to paclitaxel. The data support 
continued optimization of the new class of SMIs that block the TG2/FN complex at the interface 
between cancer cells and the tumor niche.
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Introduction:
Interactions between cancer cells and the tumor niche occur early during tumorigenesis and 
promote cell survival, evasion from chemotherapy, and establishment of metastatic sites. In 
ovarian cancer (OC), contact with the fibronectin (FN) and collagen-rich mesothelial matrix 
critically regulates the steps of peritoneal dissemination(1). We identified tissue 
transglutaminase (TG2), a protein which anchors epithelial cells into the extracellular matrix 
(ECM) through interactions with FN and integrins(2), as being highly expressed in ovarian 
tumors at the interface between cancer cells and the tumor microenvironment (TME) (3). We 
showed that when injected intraperitoneally (ip) or under the ovarian bursa of nude mice, 
OC cells engineered to express decreased levels of TG2 disseminated less efficiently, as 
compared to control cells(3–5).
The process of metastasis in solid tumors requires loss of cell-cell contact and breakdown of 
the basement membrane followed by tumor invasion into lymphatic or vascular channels(6). 
By contrast, OC harbors a distinct pattern of peritoneal metastasis, with hematogenous 
dissemination being uncommon(1). OC cells are in direct contact with the overlying 
peritoneal surface and fluid and simple dislodgement from the primary tumor allows cells to 
float in the peritoneal space, where they adhere and form metastatic implants. In the 
peritoneal fluid, OC cells aggregate as spheroids, which provide protection from the stress 
imposed by the extracellular environment. Interactions between cancer cells and the 
peritoneal mesothelium activate “outside-in” signaling (7) which stimulates cell 
proliferation, survival and tumor angiogenesis. Over the past decade, our group 
demonstrated sequentially that TG2 regulates EMT (4), migration of cells from the primary 
site(3), formation of spheroids in the peritoneal fluid (8), and invasion into the peritoneum 
(3, 9). These steps regulated by the protein through its interaction with FN contribute to 
establishment of peritoneal implants (3, 4) and render TG2 an attractive new cancer target.
TG2 is a multifunctional protein, which catalyzes Ca2+-dependent post-translational protein 
modifications and has a well-defined binding site for FN. Our mechanistic studies identified 
the interaction between TG2 and FN as being a critical player in the process of 
intraperitoneal (ip) dissemination. We demonstrated that the TG2/FN complex is implicated 
in OC metastasis via multiple mechanisms including: adhesion to the ECM by strengthening 
integrin-dependent cell-matrix adhesion (3), induction of epithelial to mesenchymal 
transition (EMT) (4, 8), regulation of Wnt/β-catenin signaling (10), through direct 
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interaction with the Frizzled 7 (Fzd7) receptor, which in turn drives OC cell proliferation 
and persistence of a stem cell profile (5), remodeling of the extracellular matrix (11), and 
fine tuning of intracellular oncogenic signaling (10, 12). An antibody that disrupted TG2/FN 
complexes inhibited cancer stemness characteristics, spheroid formation, and tumor 
initiation (5).
Based on these results, we hypothesized that the TG2/FN interaction is targetable and that its 
disruption by small molecules will prevent cancer cell adhesion to the matrix and OC 
metastasis. To this end, we completed a high throughput screening (HTS) campaign of 
compounds in the ChemDiv library by using a newly developed AlphaLISA assay that 
robustly measured the TG2/FN complex formation and identified a new class of potent 
inhibitors for this protein-protein interaction (PPI) (13). We showed that several of the small 
molecules discovered through the screen potently blocked OC cell adhesion and migration, 
demonstrating proof-of-principle for blocking this protein complex to diminish cancer cell 
invasiveness and perhaps peritoneal dissemination. The best hit (TG53) exhibited good 
biochemical potency and had highly efficacious cellular activity. Given its promising 
properties, we used TG53 as a starting point to develop more potent and selective TG2/FN 
inhibitors by using rational medicinal chemistry optimization. Here we show that newly 
synthesized analogues possess improved in vitro and in vivo efficacy in OC models. This 
new series of TG2/FN inhibitors potently blocks cellular adhesion to FN and to a 
reconstituted peritoneal matrix, resulting in inhibition of “outside-in” signaling and 
sensitization of cancer cells to paclitaxel. Our results identify new small molecules targeting 




Unless stated otherwise, chemicals and reagents were from Sigma-Aldrich (St Louis, MO, 
USA). Anti-integrin β1 antibody was from Chemicon (Cambridge, MA, USA); PE anti-
CD29/integrin β1 (#303004), from BioLegend (San Diego, CA, USA); anti-pERK1/2(# 
9101), anti-ERK (# 9102), anti-pFAK (#3283), and anti-FAK (#3285), from Cell Signaling 
(Beverly, MA, USA); anti-vinculin (#ab18058), from Abcam(Cambridge, MA, USA); anti-
pFAK(#44–625G)used for IF was from Thermo Scientific (Fremont, CA, USA);and anti-
GAPDH from Biodesign International (Saco, ME, USA). Antibodies for phospho-Src 
(Tyr416), phospho-FAK (Tyr576/577), and c-Src used for confocal imaging were from Cell 
Signaling Technology, Inc. (Beverly, MA, USA), monoclonal TG2 (CUB 7402) was from 
Thermo Fisher Scientific, integrin β1 was from EMD Millipore (Billerica, MA, 
USA).Secondary HRP-conjugated antibodies were from Amersham Biosciences (San 
Francisco, CA, USA) and Santa Cruz Biotechnology Inc (Santa Cruz, CA, USA).
Cell culture
SKOV3 cells were obtained from the American Type Culture Collection (ATCC, Manassas, 
VA), and cultured in growth media containing 1∶1 MCDB 105 (Sigma, St. Louis, MO) and 
M199 (Cellgro, Manassas, VA).OVCAR5. SKOV3-GFP, and OVCAR433 were provided by 
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Drs. Peter (Northwestern University, Chicago, IL) and Bigbsy (Indiana University, 
Indianapolis, IN), respectively, and were grown in RPMI media (Corning). LP9, a 
mesothelial cell line, was procured from the Coriell Institute (Camden, New Jersey, USA) 
and grown in M199/MCDB 151 medium with 15% FBS and 0.4 μg/ml hydrocortisone. 
Media was supplemented with 10% FBS and 1% Penicillin-Streptomycin. Cells were 
cultured at 37°C in a humidified incubator with 5% CO2. All cells were authenticated and 
tested negative for Mycoplasma at least yearly. Cells were passaged no more than 15 times 
after thawing.
Design and synthesis of TG-53 analogues.
The synthetic schemes and detailed experimental procedures are included in Supplemental 
Information. All six compounds MT-1–6 were synthesized from a common intermediate 
N2-(4-aminophenyl)-N4,N4,6-trimethylpyrimidine-2,4-diamine (compound S1, structure 
shown in Supplemental Material). Compound S1 was prepared from commercially available 
compounds crimidine and p-phenylenediamine. A solution of crimidine and p-
phenylenediamine (1:1 mole ratio) in dimethyl formamide (DMF), were sealed in a glass 
microwave reactor and radiated with microwave to heat up to 150 °C and maintained for 15 
min. After cooling to room temperature, the solid product was collected by filtration, and 
washed with ethyl acetate to give compound S1. Compound S1 was then condensed with 
different carboxylic acids in DMF, using propyl phosphonic anhydride (T3P) as the coupling 
reagent to give the desired products (MT-1–6). Compounds were purified by reversed-phase 
HPLC and purity was confirmed with LC-MS and NMR (Figures S1–S6).
Bio-layer Interferometry (BLI) and Isothermal Titration Calorimetry (ITC)
The 45kDa fibronectin fragment (FN45) corresponding to the TG2 binding region (Sigma, 
#F0162) was biotinylated using Biotin (Type A) Fast Conjugation Kit (Abcam, #ab201795). 
Biotinylated FN45 (10 μg/mL in PBS) was captured on pre-hydrated streptavidin-coated 
sensors (Pall Forte Bio SAX 18–5117). At each TG2 concentration, the binding kinetics 
were determined by following this sequence run: baseline (PBS for 30s), association step 
(varying concentrations of TG2 in PBS for 120s), and dissociation step (PBS for 120s). A 
new FN45 biosensor was prepared for each run. To analyze the effect of the inhibitor MT4 
on the interaction between TG2 and FN, a solution of 20μg/mL of bio-FN45 was used for 
capturing FN45 on the streptavidin-coated sensors and the association step was 90s. For 
each sensor, the capturing step was measured in real-time in order to assess the stability of 
the signal and the reproducibility between sensors. The saturation level Rmax was 0. 6 
(±0.08) for all sensors and no dissociation of the biotinylated FN45 was observed over 60 
minutes. Control experiments performed with bare sensors (without FN45) showed no 
significant binding of TG2. For the experiments with (TG2 + MT4), controls were 
performed at each MT4 concentration and Rmax values were corrected for non-specific 
binding and any effects of DMSO on the TG2-FN45 interaction (these effects were below 
8%). All BLI experiments were performed at 22° C. Data fitted globally using the BLItz Pro 
1.10.31 software package as described(14, 15). Isothermal titration calorimetry (ITC) was 
performed at 25 °C by titrating160 μM MT4 into a 10 μM solution of TG2 (Sigma, #T5398).
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Cell adhesion to LP9 mesothelial cells monolayers
LP9 mesothelial cells added to clear-bottom 96-well plate at 12,000 cells/well were grown to 
confluency over 48 hours (h). OC cells were labeled with calcein AM and seeded at a 
density of 4×104 cells to monolayers of mesothelial cells and incubated for 1h. Non-
adherent cells were removed by washing with PBS.
Total internal reflection fluorescence (TIRF) microscopy
For assessing the potential effect of SMIs on β1 integrin distribution at the interface between 
cells and the FN matrix, OVCAR5 cells were treated for 1h with either TG53 or MT-4 in 
serum-free media at 37°C, and then seeded onto FN-coated glass bottom microwell dishes 
(MatTek Corp. Ashland, MA) for 45 minutes at 37°C. Samples were fixed in PFA and 
blocked in 1% BSA. β1 integrin receptors were detected by using anti-β1 integrin antibodies 
(clone P5D2, Chemicon, #MAB1959, 1:100) and AlexaFluor 568-conjugated anti-mouse 
secondary antibodies, while actin was labeled using Alexa Fluor 488-conjugated phalloidin. 
Cells were imaged with a Nikon Ti2 Microscope equipped with a Photometrics Prime 95B 
camera using a Nikon Plan Apo 100× 1.49 NA TIRF objective.
In vivo cell attachment
All animal experiments were conducted in accordance with the recommendations for the 
Care and Use of Laboratory Animals of the National Institutes of Health under a protocol 
approved by Indiana University Institutional Animal Care and Use Committee. 5×106 
SKOV3-GFP cells diluted in 100μl were injected intraperitoneally (ip) along with compound 
MT4 or MT6 (10μg/kg) in six-week-old female NOD-SCID gamma (NSG) mice (Jackson 
laboratories). After 2 hours, mice were euthanized, and the peritoneal cavity was washed 
thoroughly with 4 mL PBS. The peritoneal fluid containing cells that had not adhered to the 
mesothelial layer was gently collected and cell number was determined by using the Luna 
FL Cell Counter (Logos Biosystems). Ten replicates per group were assessed.
Enzyme-linked Immunosorbent Assay (ELISA); TG2 enzymatic activity assay; CCK-8 cell 
proliferation assays; Solid phase adhesion assay; Solubility assay, Wound-healing assay; 
Early attachment assay; Immunofluorescent (IF) staining and confocal microscopy; Western 
blotting; Colony and sphere forming assays, see Supplementary material (SM) and 
published methods (5, 13, 16).
Statistical analysis
GraphPad 7.04 Software (Prism, San Diego, CA, USA) was used for all statistical analyses. 
The Student’s t test was used to test statistical significance between groups.
Results
Design and synthesis of new SMIs targeting TG2-FN interaction
Six new compounds were designed based on the chemical structure of the previously 
reported diaminopyrimidine derivative TG53 (13). The structure of TG-53 is shown in 
Figure 1. Hit optimization strategy was focused on the improvement of TG-53 potency and 
solubility. A small group of derivatives were designed to diversify the carboxylic amide 
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group of TG-53 (Figure 1). Compounds MT-3, MT-5, and MT-6 were designed to increase 
the binding activity by enhancing the potential interaction between the molecule and the 
target protein. MT-3 adds an additional chloride group at the p-position; MT-6 substitutes 
the original chlorine atom with a larger bromo group; and MT-5 replaces the benzene ring 
with a larger naphthalene ring. Compounds MT-1, MT-2 and MT-4 were designed to 
increase the solubility. MT-1 installs an amine group to replace the chloride, which should 
improve compound solubility under acidic conditions; MT-2 uses a methoxyl group to 
replace the chloride, which should improve solubility at neutral pH; and MT-4 adds an 
additional methylene group between the two aromatic groups (Figure 1), which increases the 
flexibility of the whole molecule, and thus should increase the overall solubility under all 
conditions. The measured solubility of MT4 was 91.5 μM compared to TG53 (< 5 μM; see 
SM).
In vitro inhibition of TG2/FN byMT1–6 compounds
The effects of MT1-MT6 on the interaction between rTG2 and FN42 were measured first by 
ELISA (13). MT-3, MT-4, MT-5, and MT-6 inhibited the interaction slightly more potently 
than TG53 at 10μM and similar to TG53 at 25 μM (Figure 2A). Next, BLI was employed to 
determine to kinetics of the TG2/FN interaction. As reported previously (17), TG2 and FN 
interact with high affinity. In our assay, the association and dissociation kinetics were: 
ka=5320/Ms, kd=0.0016/s (Figure 2B) and the equilibrium affinity (Kd) was 0.30nM. To 
examine the effect of MT4 on the formation of the rTG2-FN45 complex, first, FN45 was 
first captured on BLI sensors and incubated with MT4 in concentrations ranging from 16nM 
to 500μM for 15, 30, and 45 minutes. In these experiments, FN45 and rTG2 complex 
formation was not affected by MT4. Second, rTG2 was incubated with MT4, prior to BLI. 
Dose-dependent inhibition of the association between FN45 and rTG2 was observed (Figure 
2C). The interaction decreased with increasing MT4 concentrations, and a faster dissociation 
was observed in the presence of MT4 (Figure 2D), suggesting that MT4 binds to TG2 and 
disrupts the binding interface with FN. To further examine this possibility, calorimetric 
titrations of MT4 into rTG2 were performed. The observed change in enthalpy for this 
interaction, ΔH, was −20.5 kcal/mol and the apparent equilibrium dissociation constant, Kd, 
was 5.1 μM (Figure S7), supporting that MT4 interacts with TG2.
Next, the effects of TG53 and analogues on the enzymatic function of TG2 were measured 
by using a TGase colorimetric assay (18). The SMIs did not interfere with the enzymatic 
activity of TG2 (Figure S8), consistent with the fact that the enzymatic core of the protein 
(Cys277) is distinct from the FN-binding site (aa88−106)(19).
Effects of MT1–6 on cell adhesion:
To measure whether disruption of the TG2-FN complex interferes with cellular adhesion to 
the ECM, a solid phase assay quantified OC cell attachment onto FN in the presence of 
SMIs or DMSO. MT2, MT4, MT5, and MT6 potently blocked OC cells’ adhesion to FN 
(Figure 2E, *, p<0.05; **, p<0.01). Because MT-4 was active and the most soluble (see SM), 
we characterized its effects in-depth, as a representative of this series. Solid phase assays 
performed with SKOV3 (Figure 2F), OVCAR433 (Figure 2G) and OVCAR5 (Figure 2H) 
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demonstrated dose-dependent inhibitory effect of MT-4 on OC cell adhesion to FN. MT-4 
was more active than TG53 at 10μM (**, p<0.01, Figure 2G–H).
SMIs prevent the formation of stable cell contacts with the FN
It has been proposed that TG2 facilitates formation of a “bridge” connecting integrin β1 with 
FN in the ECM (2). TG2/FN/integrin complexes are known to activate downstream 
signaling. Among the key proteins engaged after cell adhesion and spreading are the focal 
adhesion kinase (FAK) and the kinase c-Src, which is required for rapid actin and F-actin 
reorganization after early spreading (20). Therefore, we next investigated how inhibition of 
TG2-FN interaction by TG-53 and related inhibitors affects integrin clustering and 
downstream signaling, by using both immunofluorescent (IF) staining and western blotting.
First, the interaction between TG2 with proteins in the integrin β1 adhesion complex was 
measured by confocal IF analysis of SKOV3 cells, in the presence or absence of 1 μM TG53 
(Figure 3A–D). A significant decrease in colocalization of TG2 with integrin β1 (Figure 
3A), phosphorylated FAK (pFAK) (Figure 3B), c-Src (Figure 3C), and phosphorylated Src 
(pSrc) (Figure 3D) was recorded. Moreover, a marked decrease in FAK and Src 
phosphorylation was observed downstream of integrin β1 upon treatment with TG53 
(Figures 3B and D).
Next, we sought to dissect the mechanism by which TG53 and related SMIs interfere with 
cell attachment. For this, we performed an in vitro early cell attachment assay using 
OVCAR5 cells pre-treated with TG53 or MT4 (1μM) for 72 hours. Cells were seeded for 30 
minutes in serum-free media onto FN coated cover slips. IF staining for vinculin showed that 
exposure of cells to both MT-4 and TG53 before and during cell attachment decreased the 
number of focal contacts established with FN-coated substrate in comparison with DMSO 
treated controls (Figure 4A, upper panel). While the vehicle treated cells established 
maturing focal adhesions (elongated shape, Figure 4A, DMSO/DMSO, inset), cells treated 
with SMIs exhibited immature contacts (punctate shape, Figure 4A, TG53/TG53, MT-4/
MT-4, insets). Increased vinculin staining around the nucleus as compared to cell periphery 
was observed in cells treated with MT4, suggesting a lack of productive engagement of cell 
protrusions to bind FN. Both TG-53 and MT4 caused decreased FAK phosphorylation 
(Figure 4A, bottom panel). Staining of actin filaments with phalloidin revealed generation of 
thin cell protrusions towards the FN surface in DMSO treated cells (Figure 4B, left panel). 
However, in cells pre-treated with MT-4, although these protrusions were formed, they could 
not establish durable connections with the FN substrate. As a consequence of mechanic 
tension, they snapped back forming curly ruffles (Figure 4B, middle panel, arrows). Also, 
cells lost polarity after exposure to MT-4 prior and during attachment, as evidenced by the 
formation of multiple lamellipodia (Figure 4B, right panel, arrows). The absence of a single 
leading-edge characteristic of directional cell migration is clearer in high-contrast grayscale 
images illustrating the actin cytoskeleton affected by MT-4 treatment (Figure 4C, right 
panel) versus TG53 (Figure 4C, left panel). MT-4 treated cells displayed cortical localization 
of actin filaments, as opposed to TG53-treated cells, where parallel intracellular actin 
filaments are still present. This provides evidence that MT-4 affects actin cytoskeleton 
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remodeling. Moreover, MT-4 affected cell-ECM adhesion, while the cell-cell interactions 
appear unaffected (Figure 4B, middle and right panel versus left panel, arrowheads).
Having observed these effects exerted by SMIs on cell adhesion and based on previous 
knowledge that cell surface TG2 promotes integrin clustering (21), we next evaluated how 
targeting TG2-FN interaction impacts integrins’ organization at the interface with FN. TIRF 
microscopy, which allows high resolution scanning at the cell-glass substrate interface 
through an evanescent light wave effect (22, 23) demonstrated that β1 integrins distribute 
evenly after OVCAR5 cells’ attachment to FN-coated substrate (Figure 4D, top panels; 
Figure S9). DMSO (control) did not affect this pattern. Actin formed dense symmetrically 
distributed filaments that support the cell shape during cellular adhesion (Figure 4D, lower 
panels; Figure S9). Pre-treatment with 1μM or 5μM TG53 caused modest displacement of 
integrin receptors towards the cell perimeter and a disorganization of the actin cytoskeleton 
that form shorter spikes instead of long stretched filaments. Noteworthy, pre-incubation of 
OVCAR5 cells with 1μM or 5μM MT-4 caused enhanced β1 integrin transposition towards 
the extreme edge of the cell concurrent with cortical positioning of actin fibers (Figure 4A–
C; Figure S9).
As a control, we used flow cytometry (FACS) to measure β1 integrin on the surface of cells 
treated with the SMIs. FACS did not show significant downregulation of β1 integrin 
receptors at the plasma membrane in SKOV3 and OVCAR5 cells treated with serial 
concentrations of TG53 and MT4, as compared to vehicle treated cells (Figure S10). As 
controls, an anti-integrin β1 function blocking antibody significantly decreased β1 integrin 
expression, while a non-specific IgG control did not cause any changes. Altogether, TIRF 
and FACS analyses indicate that the main effect of the SMIs is redistribution of β1 integrin 
receptors towards the cortical region, with only minor changes observed at the plasma 
membrane (Figure 4D and S10).
SMIs attenuate signaling downstream of integrin β1
The effects of selected SMIs on “outside in” signaling activated in response to cell adhesion 
were also measured by Western blotting. Treatment of OC cells with TG53 (8 to 16 μM) 
attenuated FAK phosphorylation (Figure S11). Similarly, MT-4 and MT-5 caused dose-
dependent inhibition of FAK phosphorylation (Figure S11). A time course experiment 
compared the effects of MT4 and of the parent compound TG53, on signaling activated in 
response to OVCAR5 cell attachment (Figure 5A). FAK phosphorylation was modestly 
delayed in the presence of TG53, with a peak in activation at 30 minutes post cell seeding on 
FN as compared to 15 minutes for control (Figure 5A, left). This inhibition was more 
evident after treatment with MT-4 (Figure 5A, right), consistent with the results of the IF 
analysis. ERK phosphorylation was also inhibited and delayed in cells treated with MT-4 as 
compared to control or TG53-treated cells (Figure 5A).
SMIs prevented attachment of OC cells to a mesothelial cell layer in vitro and to 
peritoneum in vivo
As cellular adhesion has a potential impact on OC metastasis (24), the new SMIs could be 
developed as inhibitors of peritoneal dissemination. Based on results of previous analyses, 
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MT4, MT5, and MT6 were selected for further characterization. First, cell adhesion to a 
mesothelial layer resembling the peritoneal cavity derived from LP9 normal primary 
mesothelial cells (25, 26) was assessed. Calcein-labeled OC cells were allowed to adhere to 
LP9 confluent monolayers in the presence of the SMIs or vehicle control. MT-4 and MT-5 
significantly decreased SKOV3 cell binding to the mesothelial layer (Figure 5B, 
***p<0.001, ****p<0.0001). MT4, MT5, MT6 exerted a dose-dependent inhibitory effect 
on OVCAR433 adhesion to the LP9 layer, at concentrations >10 μM (Figure 5C, **p<0.01, 
***p<0.001).
After cell adhesion to the mesothelium, the next step in the process of peritoneal metastasis, 
is migration and invasion into the matrix. Thus, effects of SMIs on OC cell migration on FN 
coated substrates were also determined. MT4, MT5 and MT6 (8μM), inhibited the motility 
of SKOV3 and OVCAR5 cells as measured by the ability to repair a scratch produced in the 
monolayer (Figure 5D–E, **p<0.01, *** p<0.001, ****p<0.0001).
Lastly, the effects of SMIs on adhesion to the peritoneum were assessed in vivo. Stably 
expressing GFP SKOV3 cells pre-incubated with MT4 or MT-6 for 1 hour were injected ip. 
Two hours after injection, unattached cells were recovered from the peritoneal cavity and 
counted (Figure S12). Increased numbers of OC cells were recovered from mice injected 
with MT4 or MT6, as compared to vehicle (Figure 5F, G). MT-4 was more potent 
(p<0.0001) than MT-6 (p<0.05) preventing attachment of SKOV3 cells to the peritoneal 
cavity. These data support further development of this class of compounds to prevent 
peritoneal dissemination.
Anti-proliferative effects:
The parent compound TG53 was not cytotoxic (13). Similarly, the analogues MT1–6 did not 
exert anti-proliferative effects in SKOV3 cells during a 72-hour treatment period (Figure 
6A–B). We next considered potential combinations of the proposed SMIs with cytotoxic 
drugs and tested whether the compounds potentiated the effects of paclitaxel (PTX). Priming 
with 1μM MT4 before PTX diminished colony formation compared to control (DMSO) or 
TG53-primed cells (Figure 6C–D). Similarly, the combination of MT-4 and PTX inhibited 
OVCAR5 cell proliferation as spheres more potently than PTX alone or PTX and TG53 
(Figure 6E–F). However, priming of OVCAR-5 cells with TG2-FN inhibitors did not 
interfere with cell cycle progression (Figure S13A) or induced apoptosis as evidenced by 
Annexin V/7-AAD double staining (Figure S13B). These results support that priming of OC 
cells with TG2-FN inhibitors potentiate effects of PTX by interfering with cell attachment to 
the FN-rich ECM, without affecting cell viability or cell cycle progression.
Discussion
Our results provide data on newly developed SMIs targeting the interaction between TG2 
and FN. We had previously reported TG53 as a lead inhibitor selected from high throughput 
screening of the ChemDiv library using an Alpha-Lisa assay (13). Here we characterize a 
series of analogues developed by using rational medicinal chemistry design and show that 
the analogues blocked TG2-FN interaction in vitro and OC cell adhesion to FN and to 
reconstituted peritoneal matrices in vitro and in vivo. Furthermore, the lead analogue, MT-4 
Sima et al. Page 9
















prevented formation of stable focal contacts and mature focal adhesions to FN. Such 
compounds are predicted to block metastasis and to increase anoikis of unattached cells in 
the peritoneal cavity. These data have several implications.
First, we provide information on a new class of SMIs which block integrin-dependent 
adhesion and “outside-in signaling”. We show that chemical optimization of the “hit” 
diaminopyrimidine compound TG-53 was possible. The strategy aimed to improve potency 
and solubility of the hit compound by modifying its amide group. The derivative compounds 
demonstrated selective binding to TG2 and improved solubility (TG53< 5μM vs. MT-4; 
91.5μM and MT-6; 6.4μM). While the proposed inhibitors demonstrate activity in vitro at 
low μM concentrations, in cellular and in vivo models, higher concentrations were required 
to attain the desired effects, suggesting that future chemical optimization of these 
compounds will be needed to improve their potency. Noteworthy, biophysical measurements 
using BLI and ITC revealed that MT-4 bound directly to TG2 and prevented its interaction 
with the FN 45 kDa fragment. This suggested that in the presence of the inhibitor, TG2 
would be prevented from bridging integrin β1 and FN in the ECM, hindering cell adhesion 
to the matrix.
Confocal microscopy supported this assumption, as TG2 colocalization with integrin β1 and 
FN in the adhesion complexes was decreased by the SMIs. In the absence of a strong 
interaction with the matrix, integrin β1 was displaced from the cell cortex, as shown by 
TIRF microscopy. Consequently, OC cells formed loose, unstable focal adhesions, with cell 
displaying curly ruffles at the plasma membrane and loss of cell polarity due to decreased 
lamellipodia in the presence of the inhibitors. This translated in a dose-dependent decrease 
of OC cells attachment to FN upon pre-treatment with the SMIs, as measured by solid phase 
assays. As TG2 was previously shown to induce integrin clustering independent from 
integrin-ligand interaction (21) and we observed partial loss of integrins colocalization in the 
presence of the SMIs, we inferred that by disrupting the interaction of TG2 with FN, integrin 
translocation from adhesion contacts was prevented and formation of an FN matrix could be 
inhibited (27). By preventing the accumulation of fibrillar FN in the tumor ECM, these TG2-
FN SMIs could have a long-term effect on tumor cells’ attachment to peritoneal sites. 
Additionally, these inhibitors will permit an in-depth evaluation of molecular events linked 
to integrin-dependent cell adhesion in contexts other than cancer.
FN is one of the most abundant ECM proteins in omentum and peritoneum (28). Adhesion 
of OC cells to FN via α5β1 integrin activates “outside-in signaling” by inducing 
phosphorylation of FAK, either directly (29) or through c-Met (30). This leads to activation 
of both survival (AKT) and mitogenic (MAPK) pathways (31), supporting cell proliferation 
and tumor growth (32). The β1 integrin-FN complex is strengthened by interactions with 
TG2, a protein we discovered to be overexpressed in OC (33). Here we show that inhibition 
of the TG2/FN complex by the new SMIs also delays and attenuates activation of FAK in 
response to cell adhesion. We had previously demonstrated the significance of TG2 to 
peritoneal dissemination through a β1 integrin dependent mechanism (3), as well as the 
significance of the TG2/FN/integrin complex to the survival of OC stem cells (5). Our 
current results using SMIs are consistent with our previous observations showing that 
targeting this complex, by using a function blocking antibody against the FN-binding 
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domain of TG2 decreased spheroid proliferation and tumor initiation capacity (34). 
Together, these data support that the TG2/FN complex is an important cancer target.
Second, we provide here the first in vivo evidence on the potential of TG2-FN inhibitors to 
interfere with peritoneal metastasis. SKOV3 cells that were pretreated with either MT-4 or 
MT-6 before injection in the peritoneal cavity of immunodeficient mice, attached less 
efficiently to the peritoneal walls, as illustrated by the increased recovery of these cells 2 
hours after inoculation. These findings were also corroborated by the solid phase assays 
performed by using LP9 cells, as a model of the peritoneal mesothelial lining, which showed 
that fewer cells attached to the mesothelial monolayer in the presence of the SMIs.
Similar cell-adhesion blocking strategies under development include the use of function-
inhibiting antibodies against integrin receptors or against the hyaluronan receptor, CD44. 
These agents were shown to prevent the attachment of OC cells to the mesothelial 
monolayer (35–37). As α5β1 integrin is expressed on both OC tumor cells as well as on 
endothelial cells (38), targeting this heterodimer was expected to interfere with tumor 
growth and dissemination in solid tumors, including in OC (30). Although promising in 
preclinical models, anti-integrin antibodies have not yet demonstrated clinical benefit in 
patients with advanced stage solid tumors (39). This could be due to their initial testing in 
late stages of the disease, after metastases had been established. Future refinement of this 
strategy targeting adhesion to the peritoneum warrants further investigation, in settings 
preceding wide-spread tumor dissemination or in combination with standard cytotoxic 
therapy.
Third, we show that priming of OC cells with TG2/FN inhibitors, sensitized cells to 
paclitaxel. A potential mechanism underlying this interaction may be related to inhibition of 
“outside-in signaling”, which provides survival signals. We and others have previously 
shown that TG2 knock down increased response to chemotherapy in breast, ovarian and 
pancreatic cancer (12, 40–42), but this is the first demonstration that inhibition of the 
interaction with FN sensitizes cancer cells to chemotherapy. This concept deserves further 
exploration along with future testing of potential synergistic combinations with other 
cytotoxic or biological anti-cancer agents. In all, our results support further development of 
TG2/FN blockade as a new strategy to inhibit peritoneal metastasis and/or to sensitize 
cancer cells to standard cytotoxic therapy. Further medicinal chemistry-based optimization 
of this class of compounds is necessary to improve their properties and bioavailability in 
vivo.
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Figure 1. Chemical structures
of TG53 (parent compound) and of the 6 derivatives targeting the TG2-FN protein-protein 
interaction (MT1-MT6).
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Figure 2. TG53 derivatives inhibit TG2-FN interaction.
A, ELISA measured the interaction between His-tagged TG2 and biotinylated FN42 in the 
presence of vehicle (DMSO, control), TG53 and MT1-MT6 at 10μM and 25μM 
concentrations. Bars represent means ± SD (n=3). B, Bio-layer Interferometry (BLI) 
sensograms monitor the real time association and dissociation kinetics of FN45 (captured on 
streptavidin-coated sensors) and TG2. The TG2 concentrations used at the association step 
are indicated. The nonlinear regression fits from 1:1 global analysis are shown as thin black 
lines; ka = 5320 M−1s−1 (±0.2%), kd =0.0016 s−1 (±0.4%), yielding KD = 0.30 nM; goodness 
of fit: R2= 0.996084. C, Concentration-dependent inhibitory effect of MT4 on the FN45-
TG2 interaction. For each MT4 concentration tested, the extent of binding (Rmax) was 
corrected for nonspecific binding of (TG2+MT4) to bare sensors. D, Bio-layer 
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Interferometry (BLI) sensograms show the real time association and dissociation kinetics of 
FN45 (20 μg/ml captured on streptavidin-coated sensors) and 1 μM TG2 pre-incubated with 
MT4 at various concentrations. E, Solid phase assay measured SKOV3 cells’ adhesion to FN 
(5μg/mL) in the presence of TG53 and MT1–6 (n = 4). F-H, Dose-dependent effect of MT4 
(2μM-25μM) on SKOV3 (F), OVCAR433 (G), and OVCAR5 (H) cells adhesion onto FN-
coated plates was measured by a solid phase assay (see SM). For all experiments, results 
represent the mean and SD of at least triplicate samples: *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001.
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Figure 3. TG53 inhibits formation of a complex with integrin β1 and activation of FAK and c-Src 
during SKOV3 cell attachment onto FN.
A–D, Confocal microscopy analysis of TG2 (Cy5, red; ×600) co-localization with integrin 
β1, p-FAK (Y576/577), c-Src, and p-c-Src (Y416) (Alexa Fluor 488, green) in the presence 
of either 1μM TG53 (lower panels) or DMSO vehicle (upper panels). Graphs quantifying co-
localization of the two proteins are presented. *p<0.05, **p<0.01.
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Figure 4. MT-4 inhibits early OVCAR5 cell attachment onto FN by interfering with the 
formation of stable focal contacts.
A–C, IF staining of adhesion complex factors in OVCAR5 cells upon cell adhesion to FN. 
A, Confocal imaging of intracellular localization of vinculin-positive focal adhesion points 
(white, upper panel), pFAK (white, lower panel), and actin filaments (green, upper and lower 
panel) at 30 minutes after seeding of OVCAR5 cells onto FN coated chamber slides in the 
presence or absence of inhibitors (TG53 and MT-4 at 1μM concentration) or vehicle 
(DMSO). Cells were treated with the SMIs for 72 hours prior to seeding and during the 
assay. Insets provide detailed view of the vinculin-positive structures. Scale bar=10μm. B, 
Analysis of the actin cytoskeleton assessed morphological differences during cell 
attachment. Scale bar=10μm. C, Grayscale images of actin cytoskeleton in TG53- (left) and 
MT4- treated cells (right). Scale bar=20μm. D, TIRF microscopy analysis of OVCAR5 cells 
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pre-treated with SMIs for 1h to determine the distribution of integrin β1 (red, upper panels) 
at the interface with FN during cell attachment. Actin cytoskeleton is depicted in green 
(lower panels). Scale bar=10μm.
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Figure 5. Effects of SMIs targeting the TG2/FN complex on “outside-in” signaling and adhesion 
to mesothelial surfaces.
A, Western blot analysis of total and phosphorylated FAK and ERK was performed using 
cell lysates extracted from OVCAR cells plated on FN for 15 to 45 minutes in the presence 
of TG53 (left) or MT-4 (right) at 5μM concentration, as compared to DMSO. GAPDH was 
used as a control. OVCAR5 cells had been pretreated with the inhibitors for 72 hours. 
Densitometry analysis used the Quantity One software and results were normalized to 
GAPDH loading controls. DMSO 0 min time point was considered as 1 for comparative 
analysis. Values are shown for each band. B, A modified cell adhesion assay measured the 
effects of TG53, MT-4, MT-5, and MT-6 (25μM) on SKOV3 cells’ adhesion onto semi-
confluent LP9 monolayers. C, Dose-dependent effects of TG53, MT-4, MT-5, and MT-6 on 
OVCAR433 cells adhesion onto semi-confluent LP9 monolayers. D–E, Wound healing 
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assay measures migration of SKOV3 and OVCAR5 cells in the presence of MT-4, MT-5, 
MT-6 at a concentration of 8 μM (black bars) or vehicle (open bar). Migration rate was 
determined over a period of 24 hours by measuring the average distance between the wound 
borders at the beginning and at the end of the assay interval (n=4). F–G, SKOV3-GFP OC 
cells were injected ip in NSG mice in the presence of either MT-4 (10μg/kg) (F) or MT-6 
(10μg/kg) (G) and allowed to attach to the peritoneal wall. After 2 hours, the cell suspension 
was recovered from the peritoneal cavity through peritoneal washings and the non-attached 
OC cells recovered were counted. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 6. Priming of OVCAR5 cells with MT-4 sensitizes cells to paclitaxel (PTX).
A–B, The CCK8 assay was used to measure cell viability of SKOV3 cells treated with 
increasing concentrations of TG53 and MT1–6 for 72 hours. C–D, Colony formation from 
OVCAR-5 cells pre-treated with 1μM MT-4 or 1μM TG53 for 72 hours before seeding in the 
presence or absence of 5nM PTX (n=6; 10 days incubation to allow colonies formation). 
Colonies were stained with 0.4% crystal violet and counted using ImageJ. E–F, Sphere 
formation assay measured proliferation of OVCAR-5 cells pre-treated with 1μM MT-4 or 
1μM TG53. Cells were allowed to form spheroids in the presence or absence of 5nM PTX (n 
= 3). Spheres were counted after ten days. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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